CN104324134B - 一种改善微循环的中药组合物及其制备方法 - Google Patents
一种改善微循环的中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN104324134B CN104324134B CN201410599419.3A CN201410599419A CN104324134B CN 104324134 B CN104324134 B CN 104324134B CN 201410599419 A CN201410599419 A CN 201410599419A CN 104324134 B CN104324134 B CN 104324134B
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- chinese medicine
- microcirculatory
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 40
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title abstract description 9
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 18
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 18
- 229940038481 bee pollen Drugs 0.000 claims abstract description 18
- 235000000235 Euphoria longan Nutrition 0.000 claims abstract description 17
- 230000003071 parasitic effect Effects 0.000 claims abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 32
- 239000012567 medical material Substances 0.000 claims description 29
- 238000000605 extraction Methods 0.000 claims description 28
- 230000024241 parasitism Effects 0.000 claims description 27
- 239000000706 filtrate Substances 0.000 claims description 19
- 239000007788 liquid Substances 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 240000001008 Dimocarpus longan Species 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 11
- 239000012467 final product Substances 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 230000006872 improvement Effects 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000003809 water extraction Methods 0.000 claims description 2
- 238000002481 ethanol extraction Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 24
- 239000008280 blood Substances 0.000 abstract description 24
- 230000004089 microcirculation Effects 0.000 abstract description 22
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 14
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 11
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 11
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 9
- 230000001225 therapeutic effect Effects 0.000 abstract description 7
- 235000013619 trace mineral Nutrition 0.000 abstract description 3
- 239000011573 trace mineral Substances 0.000 abstract description 3
- 244000139609 Euphoria longan Species 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 15
- 239000008103 glucose Substances 0.000 description 15
- 239000002671 adjuvant Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 10
- 239000006188 syrup Substances 0.000 description 9
- 235000020357 syrup Nutrition 0.000 description 9
- 239000002775 capsule Substances 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- -1 filter Substances 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 210000000038 chest Anatomy 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 208000000059 Dyspnea Diseases 0.000 description 4
- 206010013975 Dyspnoeas Diseases 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 4
- 210000001015 abdomen Anatomy 0.000 description 4
- 208000007502 anemia Diseases 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 4
- 208000002173 dizziness Diseases 0.000 description 4
- 206010016256 fatigue Diseases 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 206010022437 insomnia Diseases 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 208000013220 shortness of breath Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- 206010008190 Cerebrovascular accident Diseases 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 206010013954 Dysphoria Diseases 0.000 description 3
- 241000488974 Loranthus Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000036770 blood supply Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 201000005577 familial hyperlipidemia Diseases 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000002175 menstrual effect Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000027939 micturition Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000035900 sweating Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 241000208340 Araliaceae Species 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 206010018985 Haemorrhage intracranial Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 208000008574 Intracranial Hemorrhages Diseases 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 239000006046 creatine Substances 0.000 description 2
- 229960003624 creatine Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 229960004580 glibenclamide Drugs 0.000 description 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- 229960003105 metformin Drugs 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 206010029410 night sweats Diseases 0.000 description 2
- 230000036565 night sweats Effects 0.000 description 2
- 206010029446 nocturia Diseases 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 206010036067 polydipsia Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 244000296912 Ageratum conyzoides Species 0.000 description 1
- 235000004405 Ageratum conyzoides Nutrition 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000256836 Apis Species 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 235000016535 Capraria biflora Nutrition 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 235000014036 Castanea Nutrition 0.000 description 1
- 241001070941 Castanea Species 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 206010069729 Collateral circulation Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 208000004552 Lacunar Stroke Diseases 0.000 description 1
- 206010051078 Lacunar infarction Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 206010054805 Macroangiopathy Diseases 0.000 description 1
- 241000218922 Magnoliophyta Species 0.000 description 1
- 208000007466 Male Infertility Diseases 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 241000122904 Mucuna Species 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 244000236658 Paeonia lactiflora Species 0.000 description 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 1
- 241000124464 Paeonia veitchii Species 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241001038562 Pseudostellaria heterophylla Species 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 241000405911 Rehmannia glutinosa Species 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 241000304195 Salvia miltiorrhiza Species 0.000 description 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 1
- 241001093760 Sapindaceae Species 0.000 description 1
- 240000001638 Scurrula parasitica Species 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 230000003073 embolic effect Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000015091 medicinal tea Nutrition 0.000 description 1
- 230000008336 microcirculatory blood flow Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 210000004026 tunica intima Anatomy 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种改善微循环的中药组合物及其制备方法。该中药组合物是由以下原料制备而成:黑血藤、蜂花粉、丹参、赤芍、三七、太子参、熟地、龙眼树寄生、金樱子寄生。能有效改善机体微循环,补充人体微量元素,疏通经络、降脂、降糖作用,对心脑血管病、糖尿病有较好疗效。
Description
技术领域
本发明涉及中药领域,具体涉及一种改善微循环的中药组合物及其制备方法。
背景技术
微循环是人体新陈代谢的场所,是人体的内环境,是生命的最基本保证。正常情况下,微循环血流量与人体组织,器官代谢水平适应,使人体内各器官生理功能得以正常运行。人体的任何器官,任何部位(其中包括心脏在内)都必须要有一个正常的健康的微循环,否则就会出现相应器官的病变。
俗话说:“微循环通,不会得中风;微循环好,心肌梗塞少;微循环畅,全身都健康。”微循环几乎是百病之源,健全的微循环功能是保证体内重要器官执行正常功能的首要前提。微循环是指直接参与组织、细胞间新陈代谢物质交换的微动脉和微静脉之间的血液循环。它直接给细胞供血、供氧、供能量及有关营养物质,同时还排出对人体有害的代谢产物,例如肌酸、乳酸、二氧化碳等,这样微循环就是人体新陈代谢的场所,是人体的内环境,是生命的最基本的保证。
心脑血管疾病与人体微循环障碍有着不可分割的关系。人体的微循环直接参与细胞的新陈代谢和物质交换,直接给细胞供血、供氧、供给能量及有关营养物质,同时还将对人体有害的代谢产物如肌酸、乳酸、二氧化碳等带出体外。如果微循环内的血小板、白细胞或纤维蛋白相互粘集形成微血栓,随着血液流向全身,或沉积在血管内膜上,当拴子导致局部血流障碍后就会引起一系列症状。如神经系统发生微循环障碍时,脑细胞得不到足够的营养和氧气,同时细胞代谢产物因供血不足不能完全排出体外,会导致头痛、眩晕、失眠、多梦、记忆力衰退;重者发生中风、偏瘫、老年性痴呆、末梢神经炎等。心血管系统发生微循环障碍时,导致胸闷、心慌、心绞痛、心率不齐,重者发生心肌梗塞。人体其他各系统微循环障碍均会出现相应症状。
糖尿病患者,不论1型或2型、病情轻或重、病程长或短以及是否有并发症,都存在着明显的血液流变性障碍,这目前已得到医学界的公认,而且倍受重视。以不同粘度计对糖尿病患者检测结果一致:患者的全血粘度、血浆粘度及血清粘度都高于正常人,有并发症患者更为显著。糖尿病患者的微循环异常,在患病初期就已出现,随着病程的增加,在临床上以脏器损害引发的并发症出现而逐渐明显。糖尿病肾病和糖尿病眼底病变是糖尿病脏器微循环障碍的典型代表,糖尿病所致大血管病变的心脑血管病,也同时伴有心和脑的微循环障碍。最新医学报告表明,改善微循环有刺激细胞,促进细胞再生的功效,有激发器官形成新的侧枝循环的作用,用于糖尿病及并发症的治疗,会有意想不到的疗效。
发明内容
本发明的目的是提供一种改善微循环的中药组合物;
本发明的另一目的是提供一种改善微循环的中药组合物制备方法。
本发明的目的是通过下列的技术方案实现的:
本发明所述的改善微循环的中药组合物,它是由包括如下重量份的原料制备而成的:
黑血藤25-45份、蜂花粉35-55份、丹参10-30份、赤芍8-25份、三七2-6份、太子参2-6份、熟地3-8份、龙眼树寄生2-6份、金樱子寄生2-6份。
优选地,是由包括如下重量份的原料制备而成的:
黑血藤30-40份、蜂花粉40-50份、丹参15-25份、赤芍10-20份、三七3-5份、太子参3-5份、熟地4-6份、龙眼树寄生3-5份、金樱子寄生3-5份。
更优的,是由包括如下重量份的原料制备而成的:
黑血藤35份、蜂花粉45份、丹参20份、赤芍15份、三七4份、太子参4份、熟地5份、龙眼树寄生4份、金樱子寄生4份。
以下是本发明中药组合物的药材来源:
黑血藤,为豆科黑血藤Mucuna castanea Merr.,以老茎入药。苦;涩;性凉入肝、肾二经。补血活血;清肺润燥;通经活络。主贫血;有经不调;肺热燥咳;咳血;腰膝酸痛;风湿痹痛;手足麻木;瘫痪。
蜂花粉来源于大自然,是蜜蜂从显花植物(蜜源植物和花粉源植物)花蕊内采集的花粉粒,并加入了特殊的腺体分泌物(花蜜和唾液)混合而成了一种不规则扁圆形状物。现代研究表明,花粉能够防治脑心血管疾病,降血脂,调节神经系统,促进睡眠,调节胃肠系统功能,促进消化,治疗习惯性便秘;在调节内分泌、提高机体免疫功能、抗衰老、改善性功能、治疗男性不育症等方面有一定的效果。还有明显的防癌抑癌和保肝护肝、防止贫血、糖尿病、抗疲劳等功能。
丹参,为唇形科植物丹参Salvia miltiorrhiza Bunge.的干燥根及根茎。苦,微寒。归心、肝经。祛瘀止痛,活血通经,清心除烦。用于月经不调,经闭痛经,症瘕积聚,胸腹刺痛,热痹疼痛,疮疡肿痛,心烦不眠;肝脾肿大,心绞痛。
赤芍,为毛茛科植物芍药Paeonia lactiflora Pall.或川赤芍Paeonia veitchiiLynch的干燥根。苦,微寒。归肝经。清热凉血,散瘀止痛。用于温毒发斑,吐血衄血,目赤肿痛,肝郁胁痛,经闭痛经,症瘕腹痛,跌扑损伤,痈肿疮。
三七,为五加科植物三七Panax notoginseng(Burk.)F.H.Chen的干燥根。甘、微苦,温。归肝、胃经。散瘀止血,消肿定痛。用于咯血,吐血,衄血,便血,崩漏,外伤出血,胸腹剌痛,跌扑肿痛。
太子参,为石竹科植物孩儿参Pseudostellaria heterophylla(Miq.)Pax ex Paxet Hoffm.的干燥块根。甘、微苦,平。归脾、肺经。益气健脾,生津润肺。用于脾虚体倦,食欲不振,病后虚弱,气阴不足,自汗口渴,肺燥干咳。
熟地为玄参科植物Rehmannia glutinosa Libosch.的新鲜或干燥块根的炮制加工品。甘,微温。归肝、肾经。滋阴补血,益精填髓。用于肝肾阴虚,腰膝酸软,骨蒸潮热,盗汗遗精,内热消渴,血虚萎黄,心悸怔忡,月经不调,崩漏下血,眩晕,耳鸣,须发早白。
龙眼树寄生,为桑寄生科桑寄生属植物毛叶桑寄生Loranthus levinei Merr.的带茎枝叶。寄生于无患子科龙眼属植物龙眼树上。以全株入药。味微苦,涩,性平。入心、肝、胃经。养心安神,消炎、活血,消积散结。治虚烦失眠、胃脘痛、跌打瘀积。
金樱子寄生,为桑寄生科桑寄生属植物桑寄生Loranthus parasiticus(L.)Merr.的带茎枝叶。寄生于蔷薇科植物金樱子藤本上。以全株入药。甘、涩、平。如肺、肾、大肠经。补肾壮腰,涩精缩尿,祛风除湿,健脾止泻,敛肠,止带。治肾虚腰痛、脾虚久泻、遗精、尿频、白带过多、水肿、支气管哮喘。
本发明的另一方面是提供了本发明中药组合物的活性成分的制备方法,该方法是采用采用水提或40-80%体积百分浓度的乙醇提取制备而成。具体制备方法如下:
方案一:取全部9味药材,混合后加水提取2-3次,每次加水量相当于药材总重量的6-12倍,每次提取时间为1-3小时,合并提取液,滤过,滤液浓缩至70-80℃时相对密度为1.15-1.20的清膏,即得活性成分。
方案二:取全部9味药材,混合后用40-80%乙醇回流提取2-3次,每次乙醇用量为药材总量的4-10倍,提取时间为1-4小时,合并提取液,过滤,滤液浓缩至70-80℃时相对密度为1.15-1.20的清膏,即得活性成分。
方案三:取全部9味药材,混合后加水提取2-3次,每次加水量相当于药材总重量的6-12倍,每次提取时间为1-3小时,合并提取液,滤过,滤液浓缩至70-80℃时相对密度为1.15-1.20的清膏,加入乙醇,使含醇量为40-70%,静置12-24小时,滤过,滤液浓缩至70-80℃时相对密度为1.10-1.25的浸膏,即得活性成分。
本发明所述的改善微循环的中药,还可以与医药学上可接受的载体配合,制成各种口服制剂,如片剂、胶囊剂、口服液、糖浆剂、合剂等。
方法1:片剂
取方案一至方案三所得活性成分之一,加入片剂常用辅料,按常规生产方法制备得本发明片剂。
上述片剂常用辅料包括稀释剂、润湿剂、粘合剂、崩解剂、润滑剂之一或全部。
方法1:胶囊剂
取方案一至方案三所得活性成分之一,加入胶囊剂常用辅料,按常规生产方法制备得本发明胶囊剂。
上述胶囊剂常用辅料包括稀释剂、润湿剂、粘合剂、崩解剂、润滑剂之一或全部。
方法3:糖浆剂
取方案一至方案三所得活性成分之一,加入糖浆剂常用辅料,按常规生产方法制备得本发明糖浆剂。
上述糖浆剂常用辅料包括矫味剂、防腐剂、助溶剂之一或全部。
方法4:合剂
取方案一至方案三所得活性成分之一,加入合剂常用辅料,按常规生产方法制备得本发明合剂。
上述合剂常用辅料包括矫味剂、防腐剂之一或全部。
方法5:口服液
取方案一至方案三所得活性成分之一,溶解后净化、浓缩,加入口服液常用辅料,按常规生产方法制备得本发明口服液。
上述口服液常用辅料包括矫味剂、防腐剂、助溶剂之一或全部。
本申请人在研究传统中医辨证治疗的基础上参考现代药理研究成果,经过多年的试验,将多种配方进行筛选,找到了能有效改善微循环的中药配方。
本发明所公开的中药组合物有效成分是由黑血藤、蜂花粉、丹参、赤芍、三七、太子参、熟地、龙眼树寄生、金樱子寄生制备而成。方中黑血藤补血活血、通经活络;蜂花粉防治脑心血管疾病,降血脂,调节神经系统,调节内分泌、提高机体免疫功能,其所含丰富的微量元素可促进胰岛素分泌、维持胰岛素的结构和功能,有效控制血糖;丹参活血通经;赤芍、三七散瘀止痛,能加强和改善冠脉微循环,扩张血管的作用;能改善和治疗冠心病,供氧不足,抗血栓;太子参益气健脾、生津润肺;熟地补血益精;龙眼树寄生安神活血,消积散结;金樱子寄生补肾健脾。全方相互协同,具有改善机体微循环,补充人体微量元素,疏通经络、降脂、降糖作用。对心脑血管病、糖尿病有较好疗效。
本发明提供的一种改善微循环的中药组合物具有以下优点:
1、本发明提供的组合物制剂安全有效,具有改善机体微循环,补充人体微量元素,疏通经络、降脂、降糖作用。对心脑血管病、糖尿病有较好疗效。
2、经临床试验证明,患者经本发明所述中药组合物治疗后,心脑血管疾病患者的临床症状有明显改善,总有效率达94.2%;2型糖尿病患者的血糖有不同程度的下降,总有效率达90.36%。
3、本发明提供的中药组合物制剂,配方科学合理,工艺简单,口感好,成本低。
具体实施方式
下面通过实施例进一步说明本发明。应该理解的是,本发明的实施例是用于说明本发明而不是对本发明的限制。根据本发明的实质对本发明进行的简单改进都属于本发明要求保护的范围。除非另有说明,本发明中的乙醇量的百分数是体积百分数,v/v表示溶液的体积比。
实施例1 饮料
黑血藤2.5kg、蜂花粉3.5kg、丹参1kg、赤芍0.8kg、三七0.2kg、太子参0.2kg、熟地0.3kg、龙眼树寄生0.2kg、金樱子寄生0.2kg。取9味药材,加水提取2次,两次加水量分别为药材总重量的10倍、8倍,两次提取时间分别为2小时、1小时,合并提取液,滤过,滤液浓缩至80℃时相对密度为1.10的浓缩液,灌装,每瓶200ml,即得。
实施例2 茶剂
黑血藤4.5kg、蜂花粉5.5kg、丹参3kg、赤芍2.5kg、三七0.6kg、太子参0.6kg、熟地0.8kg、龙眼树寄生0.6kg、金樱子寄生0.6kg。取9味药材,用40%乙醇回流提取3次,每次乙醇用量分别为药材总量的10倍、8倍、4倍,提取时间分别3小时、2小时、1小时,合并提取液,过滤,滤液浓缩60℃时相对密度为1.25的浸膏,在45℃下干燥、将已干燥的干膏碎过40目筛后,装入泡袋纸中,10g/袋,即得。
实施例3 颗粒剂
黑血藤3kg、蜂花粉4kg、丹参1.5kg、赤芍1kg、三七0.3kg、太子参0.3kg、熟地0.4kg、龙眼树寄生0.3kg、金樱子寄生0.3kg。取9味药材,加水提取3次,三次加水量分别相当于药材总重量的12倍、8倍、6倍,每次提取时间分别3小时、2小时、1小时,合并提取液,滤过,滤液浓缩至70℃时相对密度为1.20的清膏,加入乙醇,使含醇量为40%,静置24小时,滤过,滤液浓缩至滤液浓缩至70℃时相对密度为1.10的浸膏,加入淀粉、糊精,制粒、干燥、整粒即得。
实施例4 胶囊剂
黑血藤4kg、蜂花粉5kg、丹参2.5kg、赤芍2kg、三七0.5kg、太子参0.5kg、熟地0.6kg、龙眼树寄生0.5kg、金樱子寄生0.5kg。取9味药材,用乙醇回流提取2次,每次乙醇浓度分别为80%、60%,每次乙醇用量分别为药材总量的10倍、8倍,提取时间分别为4小时、3小时,合并提取液,过滤,滤液浓缩至80℃时相对密度为1.10的浸膏,在浸膏中加入辅料淀粉、乙醇、糊精、硬脂酸镁,按常规方法制成胶囊剂。
实施例5 片剂
黑血藤3.5kg、蜂花粉4.5kg、丹参2kg、赤芍1.5kg、三七0.4kg、太子参0.4kg、熟地0.5kg、龙眼树寄生0.4kg、金樱子寄生0.4kg。取9味药材,三次加水量分别为药材总重量的12倍、8倍、6倍,三次提取时间分别为3小时、2小时、1小时,合并提取液,滤过,滤液浓缩至70℃时相对密度为1.25的清膏,加入辅料淀粉、乙醇、滑石粉,制得片剂。
实施例6 颗粒剂
黑血藤3kg、蜂花粉4kg、丹参2kg、赤芍1.2kg、三七0.3kg、太子参0.4kg、熟地0.7kg、龙眼树寄生0.3kg、金樱子寄生0.4kg。取9味药材,每次加水量分别相当于药材总重量的12倍、10倍,每次提取时间分别为3小时、2小时,合并提取液,滤过,滤液浓缩至80℃下相对密度为1.05的清膏,加入乙醇,使含醇量为70%,静置12小时,滤过,滤液浓缩至70℃时相对密度为1.25的浸膏,加入淀粉、糊精,制粒、干燥、整粒即得。
实施例7 糖浆剂
黑血藤4kg、蜂花粉4.5kg、丹参2.5kg、赤芍1.8kg、三七0.3kg、太子参0.3kg、熟地0.4kg、龙眼树寄生0.6kg、金樱子寄生0.4kg。取9味药材,两次加水量分别为药材总重量的10倍、8倍,两次提取时间分别为2小时、1小时,合并提取液,滤过,滤液浓缩至80℃时相对密度为1.10的浸膏。在浸膏中加入糖浆剂辅料蔗糖、山梨酸、水搅拌均匀,制得糖浆剂。
实施例8 合剂
黑血藤3.5kg、蜂花粉5.5kg、丹参2.2kg、赤芍1.5kg、三七0.5kg、太子参0.5kg、熟地0.7kg、龙眼树寄生0.2kg、金樱子寄生0.2kg。取9味药材,三次加水量分别相当于药材总重量的12倍、8倍、6倍,每次提取时间分别3小时、2小时、1小时,合并提取液,滤过,滤液浓缩至总重量为药材总重量的3倍,灌装,加入合剂辅料蔗糖、乙酯、水、山梨酸搅拌均匀,制得合剂。
临床试验
一、对心脑血管疾病的临床观察
1 一般资料
选择135例心脑血管疾病患者,经患者或家属同意后随机分为两组,治疗组68例,男37例,女31例;年龄47~76岁,平均年龄61.8岁:高血压16例,高脂血症l1例,动脉粥样硬化9例,脑梗死l1例,颅内出血9例,其他12例。对照组67例,男39例,女28例:年龄45~75岁,平均年龄62.4岁;高血压14例,高脂血症10例,动脉粥样硬化9例,脑梗死l2例,颅内出血8例,其他l4例。两组患者在年龄、性别、病情以及疾病类型等方面均具有可比性,数据经统计学处理无显著性差异(P>0.05)。
2 治疗方法
2.1 治疗组
治疗组68例患者采用口服本发明实施例4胶囊剂,一次2~4粒,每天3次,四周为一个疗程,对于轻度患者可一次2粒,每天3次;对于中、重度的患者每次4粒,每天3次。医生可根据患者的病情变化随时调整用药剂量。孕妇及妇女经期及阴虚火旺型中风禁用。
2.2 对照组
对照组67例患者给予口服银杏叶片进行治疗,一次2片,每天3次,四周为一个疗程,医生还可根据患者的病情变化随时调整用药剂量,以便合理用药。两组患者经过3个疗程的治疗后,对其临床疗效进行对比与分析。对本品过敏者禁用,心力衰竭、孕妇及过敏体质者慎用。
3 疗效评价
可根据患者疾病的不同进行不同的疗效评价,其相同点为:①显效:患者的临床症状或体征消失或明显减少,仪器检查身体各项指标恢复正常或基本恢复;②有效:患者的临床症状或体征有所减少,仪器检查身体各项指标有所恢复;③无效:患者的临床症状或体征没有变化,仪器检查身体各项指标也无恢复。总有效率即显效率与有效率的和。
4 结果
两组药物的临床疗效比较见表1。
表1 两组药物临床疗效比较
组别 | 显数 | 有数 | 无数 | 合计 | 总有效率(%) |
治疗组 | 41 | 23 | 4 | 68 | 94.12* |
对照组 | 29 | 22 | 16 | 67 | 76.12 |
注:与对照组相比,*P<0.05。
由表1可知,经过4个疗程的治疗后,治疗组总有效率为94.12%,与对照组总有效率为76.12%相比,P<0.05,两组具有显著性差异,故具有统计学意义。结果显示:本发明中药组合物对心脑血管疾病有较好的治疗作用,且疗效优于现有技术。
二、对2型糖尿病的临床观察
1 纳入标准
1.1 凡具有口渴多饮、消谷易饥、尿多而甜、形体渐见消瘦证候者即可确诊为消渴病(糖尿病)。
1.2 凡倦怠乏力,自汗盗汗、气短懒言、口渴喜饮、五心烦热、心悸失眠、溲赤便秘、舌红少津、舌体胖大、苔薄或花剥,脉弦细或数者,即为气阴两虚型糖尿病。
1.3 有糖尿病症状,任何时间血糖>11.1mmol/L或空腹血糖>7.0mmol/L。
1.4 已确定为2型糖尿病,长期服用二甲双胍的患者或长期注射胰岛素的患者。
所有患者均符合上述4条中的1条或1条以上
2 病例选择
2.1 凡同时符合上述西医分类标准、中医证候诊断标准患者;
2.2 年龄18-65岁者;
2.3 愿意接受一个月疗程治疗者;
2.4 签署进入临床研究知情同意书者。
3 一般资料
合格受试者共105例,其中治疗组83例,对照组22例,采用随机对照试验。性别:治疗组男40例,女43例;对照组男12例,女10例。年龄:治疗组(53.78±8.68)岁,对照组(52.47±8.46)岁。病情:治疗组轻21例,中43例,重19例;对照组轻6例,中12例,重4例。两组在性别、年龄、病程、病情方面均无显著性差异(P>0.05)。
4 分组及给药
4.1 治疗组:口服本发明实施例5片剂,轻度病情服用剂量为每次2片,中度病情服用剂量为每次4片,重度病情服用剂量为每次6片。均餐前0.5h服,每日2次。
4.2 对照组:口服格列本脲片(天津力生制药厂生产),轻度病情服用剂量为每次1.25mg,中度病情受试者服用剂量为每次2.5mg,重度病情受试者服用剂量为每次3.75mg,均餐前0.5h服,每日2次。
4.3 疗程
疗程为1个月
5 观测指标:治疗组和对照组每周检测空腹及餐后2h血糖,观察并记录症状变化,治疗前后检查血常规、尿常规、大便常规、心电图、肝功、肾功、糖化血红蛋白、血脂等。同时密切观察可能出现的不良反应和低血糖症状。
6 疗效判定标准
6.1 症状记分方法体倦乏力:稍倦2分,可坚持轻度体力劳动4分,勉强支持日常活动6分;口渴喜饮:饮水量3磅/d 2分,饮水量超过5磅/d 4分,饮水超过10磅/d 6分。易饥多食:超过日常主食量的10%2分,超过主食量的20%4分,超过主食量的40%6分;气短懒言:偶见气短2分,气短懒言4分,经常感到气息不能续接6分;盗汗:睡中汗出湿衣1分,睡中汗出湿被2分;便秘:2-3日大便1次1分,3日以上大便1次2分;舌象:舌红或胖大1分;脉象:脉弦细或细数1分。
6.2 疗效判定标准
6.2.1 中医证候疗效疗效指数(n)=(治疗前积分-治疗后积分)/治疗前积分×100%。显效:n≥70%,有效:30%≤n<70%,无效:n<30%。
6.2.2 血糖的疗效标准参照《中药新药治疗消渴病(糖尿病)的临床研究指导原则》制定。
7 结果
7.1 中医证候疗效结果见表2
表2 两组药物对糖尿病患者治疗效果
组别 | 显效 | 有效 | 无效 | 合计 | 总有效率(%) |
治疗组 | 48 | 27 | 8 | 83 | 90.36* |
对照组 | 9 | 5 | 8 | 22 | 63.63 |
注:与对照组相比,*P<0.05。
由表2可知,经过一个月的治疗后,治疗组总有效率为90.36%,与对照组总有效率为63.63%相比,P<0.05,两组具有显著性差异,故具有统计学意义。表明本发明中药组合物在改善气阴两虚证糖尿病患者的中医症状优于格列本脲片。
7.2 血糖改善情况
结果见表3。
表3 两组受试者血糖改善情况比较
注:与治疗前比较,*P<0.05,**P<0.01。
由表3可知,两组受试者在治疗前后的空腹血糖、餐后2h血糖、糖化血红蛋白改善都有显著性差异;而在治疗前后变化的差值上,空腹血糖、餐后2h血糖、糖化血红蛋白的组间比较均无显著性差异。
典型病例
黄XX,男,73岁。头晕,神疲欲寐,精神不振,心悸、胸闷、气急,夜尿频数,尿清,形寒怕冷,手足不温,两脚底怕冷更为显著,腹胀不适,大便偏软,一天2次。经心内科、神经内科检查诊断:高脂血症,脑动脉硬化。CT证实:多发性腔隙性脑梗塞。经西药降脂、扩张血管之类药不效。经服用本发明实施例7糖浆剂四周后,头晕若失,精力充沛,诊断为康复。
韦XX,女,56岁。于七年前无明显诱因下出现多饮、多食、多尿,伴有消瘦,每日饮水量明显增多,饭量大增,夜尿频多,平均10次/晚左右,当时无排尿困难,无尿路刺激症状,体重在七年间由60公斤渐降至45公斤,尤以近二年体重下降明显。曾外院查血糖偏高,诊断为“2型糖尿病”,曾口服消渴丸、达美康、二甲双胍等药物治疗无效。经服用本发明实施例2茶剂4周后,患者睡眠改善,情绪明显好转,空腹血糖6.7mmol/L,餐后2h血糖9.5mmol/L,糖化血红蛋白(HbAc)7.3%。汉密顿抑郁量表评分15分。
虽然,上文中已经用一般性说明、具体实施方式及试验,对本发明作了详尽的描述,但在本发明基础上,可以对之作一些修改或改进,这对本领域技术人员而言是显而易见的。因此,在不偏离本发明精神的基础上所做的这些修改或改进,均属于本发明要求保护的范围。
Claims (8)
1.一种改善微循环的中药组合物,其特征在于它是由以下重量份的中药原料制成的:
黑血藤25-45份、蜂花粉35-55份、丹参10-30份、赤芍8-25份、三七2-6份、太子参2-6份、熟地3-8份、龙眼树寄生2-6份、金樱子寄生2-6份。
2.如权利要求1所述的改善微循环的中药组合物,其特征在于它是由以下重量份的中药原料制成的:
黑血藤30-40份、蜂花粉40-50份、丹参15-25份、赤芍10-20份、三七3-5份、太子参3-5份、熟地4-6份、龙眼树寄生3-5份、金樱子寄生3-5份。
3.如权利要求1所述的改善微循环的中药组合物,其特征在于它是由以下重量份的中药原料制成的:
黑血藤35份、蜂花粉45份、丹参20份、赤芍15份、三七4份、太子参4份、熟地5份、龙眼树寄生4份、金樱子寄生4份。
4.如权利要求1-3任一项所述的改善微循环的中药组合物,其特征在于它的活性成分是采用水提或40-80%体积百分浓度的乙醇提取制备而成。
5.如权利要求4所述的改善微循环的中药组合物,其特征在于它的活性成分是通过以下方法制备而成的:取全部9味药材,混合后加水提取2-3次,每次加水量相当于药材总重量的6-12倍,每次提取时间为1-3小时,合并提取液,滤过,滤液浓缩至70-80℃时相对密度为1.15-1.20的清膏,即得活性成分。
6.如权利要求4所述的改善微循环的中药组合物,其特征在于它的活性成分是通过以下方法制备而成的:取全部9味药材,混合后用40-80%乙醇回流提取2-3次,每次乙醇用量为药材总量的4-10倍,提取时间为1-4小时,合并提取液,过滤,滤液浓缩至70-80℃时相对密度为1.15-1.20的清膏,即得活性成分。
7.如权利要求4所述的改善微循环的的中药组合物,其特征在于它的活性成分是通过以下方法制备而成的:取全部9味药材,混合后加水提取2-3次,每次加水量相当于药材总重量的6-12倍,每次提取时间为1-3小时,合并提取液,滤过,滤液浓缩至70-80℃时相对密度为1.15-1.20的清膏,加入乙醇,使含醇量为40-70%,静置12-24小时,滤过,滤液浓缩至70-80℃时相对密度为1.10-1.25的浸膏,即得活性成分。
8.一种改善微循环的药物组合物,由权利要求1-3中任一项所述的改善微循环的中药组合物与医药学上可接受的载体配合制备而成。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410599419.3A CN104324134B (zh) | 2014-10-30 | 2014-10-30 | 一种改善微循环的中药组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410599419.3A CN104324134B (zh) | 2014-10-30 | 2014-10-30 | 一种改善微循环的中药组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104324134A CN104324134A (zh) | 2015-02-04 |
CN104324134B true CN104324134B (zh) | 2017-03-15 |
Family
ID=52399024
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410599419.3A Active CN104324134B (zh) | 2014-10-30 | 2014-10-30 | 一种改善微循环的中药组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104324134B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106721679A (zh) * | 2015-11-20 | 2017-05-31 | 庞盛升 | 一种龙眼树寄生保健饮料 |
CN107711980A (zh) * | 2017-11-29 | 2018-02-23 | 庞盛升 | 一种寄生茶饼干 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004083449A (ja) * | 2002-08-26 | 2004-03-18 | Kinji Ishida | ストレス緩和用の経口投与組成物 |
CN1586574A (zh) * | 2004-07-07 | 2005-03-02 | 香港养春堂中药有限公司 | 一种降低血脂的药物 |
CN1868527A (zh) * | 2005-05-27 | 2006-11-29 | 史兴昌 | 治疗心脑血管疾病的中药 |
CN1813968A (zh) * | 2005-11-30 | 2006-08-09 | 张风国 | 治疗高脂血症和心脑血管疾病的中药及其制备方法 |
-
2014
- 2014-10-30 CN CN201410599419.3A patent/CN104324134B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN104324134A (zh) | 2015-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102526474B (zh) | 一种治疗神经衰弱的中药组合物 | |
CN101708281B (zh) | 一种养心安神的中药制剂及其制备方法 | |
CN107126485A (zh) | 一种辅助改善睡眠的中药组合物及其制备方法和应用 | |
CN105663607A (zh) | 一种中药组合物及其制备方法和用途 | |
CN103520505B (zh) | 一种治疗神经衰弱的中药制剂及制备方法 | |
CN106214964A (zh) | 安神的中药制剂 | |
CN101095768B (zh) | 一种治疗中老年原发性高血压的中药胶囊 | |
CN101700336B (zh) | 一种治疗颅脑外伤后遗性头痛的中药制剂及其制备方法 | |
CN104324134B (zh) | 一种改善微循环的中药组合物及其制备方法 | |
CN101695527B (zh) | 一种排毒润肠的中药制剂及其制备方法 | |
CN103230457B (zh) | 一种治疗病毒性心肌炎的中药组合物及其制备方法与用途 | |
CN103393938B (zh) | 一种降血糖的中药组合物 | |
CN106038743A (zh) | 一种降血压冲剂、制备方法及其应用 | |
CN105194355A (zh) | 一种治疗原发性高血压的中药制剂 | |
CN105833043A (zh) | 一种中药组合物在制备治疗原发性高血压药物中的用途 | |
CN104352973A (zh) | 一种用于产后抑郁的中成药 | |
CN103349709B (zh) | 一种益气养阴、滋补肝肾的中药制剂 | |
CN116440224B (zh) | 一种中药组合物、制剂及制备方法 | |
CN106581299A (zh) | 一种改善中老年肾气虚证的中药组合物及其应用 | |
CN102836320B (zh) | 治疗快速型心律失常的中药丸 | |
CN105770520A (zh) | 一种用于治疗冠心病的药物制剂及其用途 | |
CN104815179A (zh) | 一种治疗神经衰弱性睡眠障碍的中药组合物及其制备方法 | |
CN104383441A (zh) | 一种治疗产后抑郁中成药的制备方法 | |
CN104688855A (zh) | 一种治疗慢性疲劳综合症的黄连阿胶组合物及其应用 | |
CN104288643A (zh) | 一种治疗虚劳遗精的药物组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240115 Address after: Room 701, No. 57-1, Xinjie Avenue, Huadu District, Guangzhou City, Guangdong Province, 510000 (Location: Room 713) Patentee after: Zhongke Haolin Biotechnology Co.,Ltd. Address before: No. 088, Ma Zhishi Team, Shiping Village, Dungu Town, Bobai County, Yulin City, Guangxi Zhuang Autonomous Region, 537600 Patentee before: Liang Xiaoqiong |